TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05834192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Backward treadmill walking
Description: Backward Treadmill walking will be given to this group. Speed settings of treadmill will be established based on the previous motor function of participants. All participants will receive conventional physical exercises which includes general mobility and functional activities. In this study, the 40-minute training programs for both groups will be occur 5 times a week for 6 weeks, with 5 minutes being allocated for warm up, 30 minutes devoted to the main exercise, and 5 minutes for cool down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower extremity cross training
Description: For cross-training, a strong resistance will be applied by the therapist until a response will be achieved on the contralateral lower extremity at the end range of motion. Resistance will be consistently applied for 10 seconds once a response will be achieved.~All participants will receive conventional physical exercises which includes general mobility and functional activities. In this study, the 40-minute training programs for both groups will be occur 5 times a week for 6 weeks, with 5 minutes being allocated for warm up, 30 minutes devoted to the main exercise, and 5 minutes for cool down.
Study: NCT05019170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-based Financial Incentives
Description: Financial Incentives - Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples \< 6 ppm will be considered negative and those \> 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced, and incentives will be contingent on submitting a negative saliva cotinine test.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best Practices
Description: Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at assessments that take place during pregnancy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Practices
Description: Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at assessments that take place during pregnancy.
Study: NCT05302440

Intervention type: DEVICE
Intervention: remote real-time health monitoring system with ring-like sensor
Description: The remote monitoring system will constantly record the temperature, pulse and SpO2 of the residents wearing the equipment. When the staff find abnormal vital signs, they will provide further medical assistance. All care staff who manage the system will be complete a very brief survey (1-minute) after each work shift for 14 days.
Study: NCT04157192

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Real acupuncture
Description: The patient will be treated for migraine with real acupuncture.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture (placebo group)
Description: Sham acupuncture is used as a control in scientific studies to test the efficacy of acupuncture in the treatment of various disorders, in this case, migraine. In this study, the subjects will not know whether they are getting true acupuncture or not. In the placebo group, the acupuncture needles will not actually be inserted into the skin. Placebo needles consisting of a sliding tube and a retractible needle are applied to the acupunture reference point (marked by a pastille stuck on the skin). The patient should not be able to feel the difference between real acupuncture and sham acupuncture.
Study: NCT05294965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenoterol
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenoterol
Description: Intravenous infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild cold exposure
Description: Body surface cooling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild cold exposure
Description: Body surface cooling
Study: NCT04697953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brolucizumab
Description: Pre-filled Syringes for intravitreal injection
Study: NCT05728697

Intervention type: DEVICE
Intervention: Endoscopic ultrasound shear wave elastography
Description: To perform the portion of the endoscopic ultrasound exam using this device, the endoscopic ultrasound probe is placed onto the surface of the stomach with the probe facing the left liver. The probe then transmits shear waves that propagate through the tissue. The waves themselves are ultrasound waves and are harmless. This is repeated 10 times on a region of interest as guided by the endoscopic ultrasound probe. The device used in question is the linear EUS (Aloka Arietta 850, Olympus America, Center Valley, PA).
Study: NCT04731259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-04
Description: ATR-04 is a proprietary formulated product containing lyophilized SEΔΔΔ, a Staphylococcus epidermidis genetically modified to be auxotrophic to D-alanine as the active ingredient.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05688618

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteroccocus Facieum and Agave Inulin
Description: A pack of symbiotic powder with 1 gram of e. facieum and 8g of agave inulin will be administered daily for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pack of unsweetened almond powder milk will be administered daily for 8 weeks
Study: NCT05111405

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CMC Arthroplasty
Description: Surgical intervention to treat CMC arthritis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CMC Arthroplasty
Description: Surgical intervention to treat CMC arthritis
Study: NCT05864677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrolysin
Description: Patients, who will be randomized to group CER, will receive Cerebrolysin at the dose of 50 mL before surgery, followed by 50 mL on the morning of days 1,2,3, and 4.
Study: NCT05280197

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Transversus abdominis plane (TAP) nerve block with liposomal bupivacaine plus free bupivacaine

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP block
Description: Transversus abdominis plane (TAP) nerve block with normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine plus free bupivacaine
Description: TAP block using liposomal bupivacaine plus free bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: TAP block using normal saline
Study: NCT04751682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV154 Vaccine
Description: Replication deficient Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) NLT 1X10\^10 Virus Particle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV154 Vaccine
Description: Replication deficient Adenoviral vector-based (expressing a stabilized spike protein) SARS-CoV-2 vaccine (BBV154) NLT 1X10\^10 Virus Particle.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06474065

Intervention type: PROCEDURE
Intervention: Myomectomy
Description: Patients submitted to operation of fibroids removal
Study: NCT05352945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyPNOS self-hypnosis mask from DREAMINZZ
Description: The use of the HyPNOS self-hypnosis mask from DREAMINZZ allows patients to immerse themselves in a state of self-hypnosis.~A Hypnos session is a narrative accompanied by spatialized sounds (3D) and ambiance for an immersive experience.~We aim to evaluate the use of the HyPNOS mask in the management of pain and anxiety in botulinum toxin injections
Study: NCT03851081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given IV
Study: NCT06064747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LF-rTMS
Description: LF-rTMS group: using 8 coil,1-Hz rTMS to stimulate the M1 region of the ipsilateral hemisphere, the stimulation intensity was RMT 100%, 1200pulses/session, two sessions (2400 pulses)/day (interval ≥ 2 hours), lasting 3 days (total 6 sessions, 7200pulses);

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation group: the sham stimulation coil was used to stimulate the same site, duration and sound as the LF-rTMS group, ensuring no effective stimulation, twice a day for 3 days.
Study: NCT06463236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guiding treatment
Description: Standardized guidance for anemia treatment by grassroots doctors using the maintenance hemodialysis renal anemia management process

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: empirical therapy
Description: Experiential treatment by grassroots doctors
Study: NCT04737837

Intervention type: DRUG
Intervention: lacosamide
Description: lacosamide as first add on therapy

Intervention type: DRUG
Intervention: lacosamide
Description: lacosamide as first add on therapy
Study: NCT05036954

Intervention type: DEVICE
Intervention: EyeBrid Excel hybrid lenses
Description: new lenses
Study: NCT06274242

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Haruna
Description: Mixed Natural Prebiotic-Fibers (Ginkgo nut, Spinach, Corn, Brown rice)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: Isolate Soy Protein and Isomalt
Study: NCT05147337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2511
Description: E2511 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2511
Description: E2511 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2511
Description: E2511 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2511
Description: E2511 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2511
Description: E2511 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2511
Description: E2511 tablets.
Study: NCT05761119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The focus of the intervention is on exercises that can improve venous return, and consists of progressive walking training at moderate and high intensity as well as guidance on physical activity. The training program is inspired by the WHO's recommendations for physical activity. The training program consists of a 14-day introductory period based on an initial interview with a physiotherapist, where the aim is to hit 30 min. times/day at moderate intensity. After 14 days, the patient receives physiotherapeutic guidance in physical activity and is introduced to the next period of 14 days, where the activity level is maintained, and the goal is to further achieve 2 x 20 min./week of high-intensity physical activity. After one month of training, the patient will be guided on maintaining and possibly progressing physical activity.
Study: NCT04360473

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine plus general anesthesia
Description: ketamine 0.3 mg / kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate plus general anesthesia
Description: Magnesium sulfate 40 mg / kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine plus magnesium sulfate plus general anesthesia
Description: Ketamine 0.15 mg/kg plus magnesium sulfate 20 mg/kg 15 minutes before balanced general anesthesia. Induction with lidocaine, fentanyl, propofol and cisatracurium. Maintenance with sevoflurane
Study: NCT06387446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Valve transplant
Description: Heart valves from an organ donor will be transplanted into recipient
Study: NCT06122467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EQ Exfoliating Cleanser
Description: Product contains: Purified water, disodium laureth sulfosuccinate, coco betaine, decyl glucoside, Juglans regia (walnut) shells, PEG-40 hydrogenated castor oil, sodium cocoyl isethionate disodium cocoyl glutamate, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), Aloe barbadensis (aloe vera) leaf juice concentrate (Aloe barbadensis leaf juice, potassium sorbate, sodium benzoate, citric acid).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EQ Gel
Description: Product contains: Purified water, witch hazel (containing 14% grain alcohol), PEG-40 hydrogenated castor oil, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), xanthan gum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EQ Moisturizer
Description: Product contains: Purified water, glycerin, dicaprylyl carbonate, cetyl alcohol, glyceryl stearate citrate, squalane, PEG-40 hydrogenated castor oil, caprylic/capric triglycerides, stearic acid, jojoba oil, phenoxyethanol SA (phenoxyethanol, caprylyl glycol, sorbic acid), ethoxydiglycol, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), allantoin, sodium carbomer.
Study: NCT06217445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high intensity focused ultrasound
Description: High-intensity focused ultrasound (HIFU) therapy is becoming more familiar in medical field because it is non-invasive technique with fewer side effects and provides promising therapeutic results. Several HIFU therapy applications have approved by many approval authorities of deferent countries since last decade

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doubled chin exercises
Description: 1. Straight jaw jut. 2-ball exercise. 3-Pucker up 4. Tongue stretch 5. Neck stretch 6-bottom jaw jut.
Study: NCT06187233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: binaural music
Description: In the binaural music group, an MP3 player and in-ear stereo headphones were provided. Music therapy was applied during the procedure.
Study: NCT05255445

Intervention type: BIOLOGICAL
Intervention: Red Blood Cell (RBC) Transfusion
Description: Simple RBC transfusion or partial manual exchange

Intervention type: BIOLOGICAL
Intervention: Red Blood Cell (RBC) Transfusion
Description: Simple RBC transfusion or partial manual exchange

Intervention type: BIOLOGICAL
Intervention: Red Blood Cell (RBC) Transfusion
Description: Simple RBC transfusion or partial manual exchange
Study: NCT05637190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expressive Arts Therapy group intervention
Description: Art is helpful to reduce negative emotions and boost self-worth during the creative process. During the Expressive Arts Therapy workshops, participants experience different art forms, including visual art, body movement, writing, music, and guided imagery to identify the inner self and get in touch with the self to release suppressed emotions and stress.
Study: NCT06114771

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strepsilis
Description: Throat lozenge (strepsilis) was given to patients 30 minutes before the operation (the dissolution rate of the lozenge was proven to be 6-9 minutes).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar dragee in the same size and shape was given to 30 patients 30 minutes before the operation. In order not to cause any complications, sugar patients were sucked and told not to chew.
Study: NCT05147337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2511
Description: E2511 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2511
Description: E2511 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2511 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2511 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2511 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2511 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2511 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2511 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2511 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2511 matched placebo tablets.
Study: NCT04669145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Dosing and volume will vary based on type of block used and weight of patient because of the pediatric population in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Dosing and volume will vary based on type of block used and weight of patient because of the pediatric population in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Dosing and volume will vary based on type of block used and weight of patient because of the pediatric population in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Dosing and volume will vary based on type of block used and weight of patient because of the pediatric population in the study.
Study: NCT05928468

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LYB002V14
Description: Participants receiving one or two boost doses of LYB002V14 after a three-dose primary series of inactivated COVID-19 vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LYB002V14A
Description: Participants receiving one or two boost doses of LYB002V14A after a three-dose primary series of inactivated COVID-19 vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LYB002CA
Description: Participants at 18-59 years old receiving two boost doses of LYB002CA after a three-dose primary series of inactivated COVID-19 vaccine.
Study: NCT05186311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capillary Blood Collection System
Description: Test Blood Sample Collection
Study: NCT05090189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: The present intervention will consist of a 6-month long, twice-weekly, home-based, monitored exercise training program, with training sessions lasting around 40 minutes, with 48 sessions in total. The program will be delivered in the form of 6 x 4-week blocks, which will progressively increase in intensity and complexity, as the participants physical capacities develop. Additionally, and in addition with current physical activity guidelines, participants will be instructed to perform at least an additional 70 minutes of purposeful activities per week. Study trainers will discuss the content of these activities with each individual participant to facilitate selection of suitable activities (e.g., brisk walking, jogging, stair climbing or bike riding), but their selection will be left to the discretion of the individual participants, and activity logs will be maintained throughout the study period.
Study: NCT05416567

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular embolization
Description: Therapeutic endovascular embolization in general anesthesia
Study: NCT06427733

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract
Study: NCT04955899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Stimulation
Description: The Galvani System will be implanted in eligible participants, and stimulation will be turned ON
Study: NCT04386070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP301
Description: RESP301 is a formulation consisting of three agents already used in clinical practice: mannitol, sodium nitrite and citric acid. Delivered by a vibrating mesh nebuliser three times per day (TID) (at least 4 hours apart), for 7 days. Each dose of RESP301 is a 6ml admixture of 150mM NaNO2, 50mM mannitol and 100mM citric acid, buffered at pH 5.4.
Study: NCT06485011

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paltysma suturing
Description: platysma muscle was sutured in this group with vicryl
Study: NCT04833348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor function measurement using inertial sensors
Description: Measurement of motor skills at M0: start of the administration of the innovative therapy and then 1 month, 3 months, 6 months, 1 year and then 2 years later:~* Free motor skills in the supine position~* Motricity in the supine position stimulated by a play frame~* Measurement of the proximal and distal activity of the upper limbs in motor skills stimulated by the play gantry~* Measurement of activity in a supported sitting position Longitudinal study, the subject is his own control
Study: NCT04817423

Intervention type: OTHER
Intervention: No intervention
Description: No intervention